| 1.475 -0.055 (-3.59%) | 04-29 11:14 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.12  |
1-year : | 2.61 |
| Resists | First : | 1.81 |
Second : | 2.23 |
| Pivot price | 1.86 |
|||
| Supports | First : | 1.13 |
Second : | 0.94 |
| MAs | MA(5) : | 1.7 |
MA(20) : | 1.8 |
| MA(100) : | 1.41 |
MA(250) : | 1.6 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 12.8 |
D(3) : | 31.5 |
| RSI | RSI(14): 41.3 |
|||
| 52-week | High : | 3.07 | Low : | 0.87 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ BMEA ] has closed below the lower bollinger band by 4.6%. Bollinger Bands are 42.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.75 - 1.76 | 1.76 - 1.77 |
| Low: | 1.51 - 1.52 | 1.52 - 1.53 |
| Close: | 1.52 - 1.53 | 1.53 - 1.55 |
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Tue, 28 Apr 2026
Phase 2 icovamenib T1D data from Biomea Fusion (NASDAQ: BMEA) show 52% C-peptide gain - Stock Titan
Mon, 27 Apr 2026
In a small T1D trial, 12 weeks of treatment preserved C-peptide for 52 weeks - Stock Titan
Mon, 27 Apr 2026
Biomea Fusion (NASDAQ: BMEA) sets 2026 virtual meeting, director votes and Deloitte audit - Stock Titan
Fri, 03 Apr 2026
Biomea Fusion (BMEA) interim CEO awarded 667,477 options at $1.49 strike - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 7.2 (%) |
| Held by Institutions | 37.3 (%) |
| Shares Short | 12,770 (K) |
| Shares Short P.Month | 11,330 (K) |
| EPS | -1.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.4 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -73.4 % |
| Return on Equity (ttm) | -152.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -70 (M) |
| Levered Free Cash Flow | -42 (M) |
| PE Ratio | -1.26 |
| PEG Ratio | 0 |
| Price to Book value | 3.62 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|